EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Klinische Studie (Phase I)Open Access · CC BY-NC-ND 4.0

F‐SHARP: a Phase I/II trial of focal salvage high‐dose‐rate brachytherapy for Radiorecurrent prostate cancer

Abhishek A Solanki iD, Ryan K Yoo, William Adams, Elai Davicioni, Michael L Mysz, Steven Shea, Gopal N Gupta, Timothy Showalter, Aurelie Garant, Courtney Hentz, Ahmer Farooq, Kristin Baldea und 2 weitere

BJU International · 2024

DOI: 10.1111/bju.16150 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift BJU International, 2024. Verfasst von Abhishek A Solanki und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Stritch School of Medicine, Cardinal Bernardin Cancer Center, Loyola University Chicago, Maywood, IL, USA. Hauptthemen laut MEDLINE: Brachytherapy, Prostatic Neoplasms. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background Intraprostatic local radiorecurrence (LRR) after definitive radiation is being increasingly identified due to the implementation of molecular positron emission tomography (PET)/computed tomography (CT) imaging for the evaluation of biochemical recurrence. Salvage high‐dose rate (HDR) brachytherapy offers a promising local therapy option, with encouraging toxicity and efficacy based on early series. Furthermore, the incorporation of advanced imaging allows for focal HDR to further reduce toxicity to maximise the therapeutic ratio. The objectives of the ‘focal salvage HDR brachytherapy for locally recurrent prostate cancer in patients treated with prior radiotherapy’ (F‐SHARP) trial are to determine the acute and late toxicity and efficacy outcomes of focal salvage HDR brachytherapy for LRR prostate cancer. Study Design The F‐SHARP is a multi‐institutional two‐stage Phase I/II clinical trial of salvage focal HDR brachytherapy for LRR prostate cancer enrolling patients at three centres. Endpoints The primary endpoint is the acute radiation‐related Grade ≥3 Common Terminology Criteria for Adverse Events (CTCAE, version 4.03) genitourinary (GU) and gastrointestinal (GI) toxicity rate, defined as within 3 months of brachytherapy. Secondary endpoints include acute and late CTCAE toxicity, biochemical failure, patterns of clinical progression, disease‐specific and overall survival, and health‐related quality of life, as measured by the International Prostate Symptom Score and 26‐item Expanded Prostate Cancer Index Composite instruments. Patients and Methods Key eligibility criteria include: biopsy confirmed LRR prostate adenocarcinoma after prior definitive radiation therapy using any radiotherapeutic modality, no evidence of regional or distant metastasis, and cT1–3a Nx or N0 prostate cancer at initial treatment. All patients will have multiparametric magnetic resonance imaging and molecular PET/CT imaging if possible. In Stage 1, seven patients will be accrued. If there are two or more GI or GU Grade ≥3 toxicities, the study will be stopped. Otherwise, 17 additional patients will be accrued (total of 24 patients). For Stage 2, the cohort will expand to 62 subjects to study the efficacy outcomes, long‐term toxicity profile, quality of life, and compare single‐ vs multi‐fraction HDR. Transcriptomic analysis of recurrence biopsies will be performed to identify potential prognostic and predictive biomarkers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BrachytherapyProstatic NeoplasmsMaleHumansPositron Emission Tomography Computed TomographyQuality of LifeNeoplasm Recurrence, LocalRadiotherapy DosageSalvage Therapy

Stichwörter der Autor:innen

biochemical recurrencebrachytherapydecipherfocalhigh-dose-rateintraprostatic recurrenceprostate cancerradiorecurrencere-irradiationsalvage local therapy

Autor:innen und Institutionen

  • Department of Radiation Oncology, Stritch School of Medicine, Cardinal Bernardin Cancer Center, Loyola University Chicago, Maywood, IL, USA.
  • Department of Radiation Oncology, Loyola University Medical Center, Maywood, IL, USA.
  • Department of Medicine, Stritch School of Medicine, Loyola University Chicago, Loyola University Medical Center, Maywood, IL, USA.
  • Veracyte, Inc., South San Francisco, California, USA.
  • Department of Radiology, Stritch School of Medicine, Loyola University Chicago, Loyola University Medical Center, Maywood, IL, USA.
  • Department of Urology, Stritch School of Medicine, Loyola University Chicago, Loyola University Medical Center, Maywood, IL, USA.

ORCID-Profile: Abhishek A Solanki

Zitieren

APA

Solanki, A. A., Yoo, R. K., Adams, W., Davicioni, E., Mysz, M. L., Shea, S., Gupta, G. N., Showalter, T., Garant, A., Hentz, C., Farooq, A., Baldea, K., Small, W., & Harkenrider, M. M. (2024). F‐SHARP: a Phase I/II trial of focal salvage high‐dose‐rate brachytherapy for Radiorecurrent prostate cancer. BJU International. https://doi.org/10.1111/bju.16150

Vancouver

Solanki AA, Yoo RK, Adams W, Davicioni E, Mysz ML, Shea S, et al. F‐SHARP: a Phase I/II trial of focal salvage high‐dose‐rate brachytherapy for Radiorecurrent prostate cancer. BJU International. 2024. doi:10.1111/bju.16150

BibTeX
@article{Solanki2024,
  author = {Solanki, Abhishek A and Yoo, Ryan K and Adams, William and Davicioni, Elai and Mysz, Michael L and Shea, Steven and Gupta, Gopal N and Showalter, Timothy and Garant, Aurelie and Hentz, Courtney and Farooq, Ahmer and Baldea, Kristin and Small, William and Harkenrider, Matthew M},
  title = {F‐SHARP: a Phase I/II trial of focal salvage high‐dose‐rate brachytherapy for Radiorecurrent prostate cancer},
  journal = {BJU International},
  year = {2024},
  doi = {10.1111/bju.16150}
}
Kostenlos starten →